

10/579111**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Bryan, et al.

IAP20 Rec'd PCT/PTO 11 MAY 2006

Serial No. To Be Assigned

Filed: May 11, 2006

For: OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST

Art Unit: _____

Examiner: _____

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.By Christin Coffe Date 5-11-06

INFORMATION DISCLOSURE STATEMENT
11 MAY 2006

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Alysia A. Finnegan

Attorney _____ For Applicant(s)

Reg. No. 48,878

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-2583

Date: May 11, 2006

COMPLETE IF KNOWN

To Be Assigned

May 11, 2006

Bryan, et al. 11 MAY 2006

Examiner Name

1

of

3

Attorney Docket Number

21561P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		PCT	WO 98/34640		Merck & Co., Inc.	08/13/1998
		PCT	WO 99/02694		The University of Queensland	01/21/1999
		PCT	WO 00/09157		Merck & Co., Inc.	02/24/2000
		PCT	WO 01/14416 A2		Merck & Co., Inc.	03/01/2001
		PCT	WO 02/08435 A1		Glaxo Group Limited	01/31/2002
		PCT	WO 2004/084831 A2		Merck & Co., Inc.	10/07/2004
		PCT	WO 2005/032586		Merck & Co., Inc.	04/14/2005

Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	To Be Assigned 579111	
			Filing Date	May 11, 2006	
			First Named Inventor	Bryan, et al.	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	3	Attorney Docket Number	21561P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Bosch, et al., "The casual relation between human papillomavirus and cervical cancer", J. Clin. Path., Vol. 55, pp. 244-265, 2002.
		Breitbart, et al., "Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect against Experimental CRPV Infection", J. of Virol., Vol. 69, No. 6, June 1995, pp. 3959-3963.
		GenBank Accession No. NC_001443.
		Guo, et al., "Signals Sufficient for 3'-End Formation of Yeast mRNA", Mol and Cell Biology, Vol. 16, No. 6, pp. 2772-2776, June 1996.
		Guo, et al., "3'-end-forming signals of yeast mRNA", TIBS 21, pp. 477-481.
		Heidmann, et al., "Flexibility and Interchangeability of Polyadenylation Signals in Saccharomyces cerevisiae", Mol. and Cell Biology, Vol. 14, No. 7, 1994, pp. 4633-4642.
		Henikoff, et al., "Transcription Terminates in Yeast Distal to a Control Sequence", Cell., Vol. 33, June 1983, pp. 607-614.
		Hofmann, et al., "Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-Like Particles in Saccharomyces cerevisiae", Virology, Vol. 209, 1995. pp. 506-518.
		Jansen, et al., "Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papillomavirus formation", Vaccine, Vol. 13, No. 16, 1995, pp. 1509-1514.
		Kirii, et al., "Human Papillomavirus Type 58 DNA Sequence", Virology, Vol. 185, 1991, pp. 424-427.
		Kotula, et al., "Evaluation of Foreign Gene Codon Optimization in Yeast: Expression of a Mouse IG Kappa Chain", Biotechnology, Vol. 9, December 1991, pp. 1386-1389.
		Liu, et al., "Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhanced prophylactic and therapeutic efficacy", Vaccine, Vol 20, 2002, pp. 862-869.
		McMurray, et al., "Biology of human papillomaviruses", J. Exp. Path., Vol. 82, 2001, pp. 15-33.
		Russo, et al., "Saccharomyces cerevisiae mRNA 3' End Forming Signals are also Involved in Transcription Termination", Yeast, Vol. 11, 1995, pp. 447-453.
		Schiffman, et al., "Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia", J. of National Cancer Inst., Vol. 85, Vol 12, 1993, pp. 958-964.

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN	
			Application Number	To Be Assigned 507579111
			Filing Date	May 11, 2006
			First Named Inventor	Bryan, et al. 11 MAY 2006
			Group Art Unit	
			Examiner Name	
Sheet 3	of 3	Attorney Docket Number	21561P	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Schiller, et al., "Papillomavirus-Like Particles: Basic and Applied Studies", UK: Leeds Medical Information, 1996, pp. 101-112.
		Schiller, et al., "Papillomavirus-Like Particle Vaccines", J. Natl. Cancer Inst. Monographs, No. 28, 2000, pp. 50-54.
		Schiller, et al., "Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report", J. of Clin. Virology., Vol 19, 2000, pp. 67-74.
		Sharp, et al., "Synonymous Codon Usage in Saccharomyces cerevisiae", Yeast, Vol. 7, 1991, pp. 657-678.
		Suzich, et al., "Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas", PNAS USA, Vol. 92, December 1995, pp. 11553-11557.
		Thalenfeld, et al., "oli 1 Transcripts in Wild Type and in a Cytophasmic 'Petite' Mutant of Yeast*", J. of Biol Chem., Vol. 258, No. 23, December 10, 1983, pp. 14065-14065.
		Tobery, et al., "Effect of vaccine delivery system on the induction of HPV 16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques", Vaccine, Vol. 21, 2003, pp. 1539-1547.
		Zaret, et al., "DNA Sequence Required for Efficient Transcription Termination in Yeast", Cell, Vol. 28, March 1982, pp. 563-573.
		Zaret, et al., "Mutationally Altered 3' Ends of Yeast CYC1 mRNA Affect Transcript Stability and Translational Efficiency", J. Mol. Biol., Vol. 176, 1984, pp. 107-135.
		Zhou, et al., "Papillomavirus Capsid Protein Expression Level Depends on the Match Between Codon Usage and tRNA Availability", J. of Virol., Vol. 73, No. 6, June 1999, pp. 4972-4982.

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005